TY - JOUR
T1 - Utilization of antihypertensives, antidepressants, antipsychotics, and hormones in Alzheimer disease
AU - Zhu, Carolyn W.
AU - Livote, Elayne E.
AU - Kahle-Wrobleski, Kristin
AU - Scarmeas, Nikolaos
AU - Albert, Marilyn
AU - Brandt, Jason
AU - Blacker, Deborah
AU - Sano, Mary
AU - Stern, Yaakov
PY - 2011/4
Y1 - 2011/4
N2 - This study explores the longitudinal relationship between patient characteristics and use of 4 drug classes (antihypertensives, antidepressants, antipsychotics, and hormones) that showed significant changes in use rates over time in patients with Alzheimer disease. Patient/caregiver-reported prescription medication usage was categorized by drug class for 201 patients from the Predictors Study. Patient characteristics included use of cholinesterase inhibitors and/or memantine, function, cognition, living situation, baseline age, and sex. Assessment interval, year of study entry, and site were controlled for. Before adjusting for covariates, useage increased for antihypertensives (47.8% to 62.2%), antipsychotics (3.5% to 27.0%), and antidepressants (32.3% to 40.5%); use of hormones decreased (19.4% to 5.4%). After controlling for patient characteristics, effects of time on the use of antidepressants were no longer significant. Antihypertensive use was associated with poorer functioning, concurrent use of memantine, and older age. Antipsychotic use was associated with poorer functioning and poorer cognition. Antidepressant use was associated with younger age, poorer functioning, and concurrent use of cholinesterase inhibitors and memantine. Hormone use was associated with being female and younger age. Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine.
AB - This study explores the longitudinal relationship between patient characteristics and use of 4 drug classes (antihypertensives, antidepressants, antipsychotics, and hormones) that showed significant changes in use rates over time in patients with Alzheimer disease. Patient/caregiver-reported prescription medication usage was categorized by drug class for 201 patients from the Predictors Study. Patient characteristics included use of cholinesterase inhibitors and/or memantine, function, cognition, living situation, baseline age, and sex. Assessment interval, year of study entry, and site were controlled for. Before adjusting for covariates, useage increased for antihypertensives (47.8% to 62.2%), antipsychotics (3.5% to 27.0%), and antidepressants (32.3% to 40.5%); use of hormones decreased (19.4% to 5.4%). After controlling for patient characteristics, effects of time on the use of antidepressants were no longer significant. Antihypertensive use was associated with poorer functioning, concurrent use of memantine, and older age. Antipsychotic use was associated with poorer functioning and poorer cognition. Antidepressant use was associated with younger age, poorer functioning, and concurrent use of cholinesterase inhibitors and memantine. Hormone use was associated with being female and younger age. Findings suggest accurate modeling of the Alzheimer disease treatment paradigm for certain subgroups of patients should include antihypertensives and antipsychotics in addition to cholinesterase inhibitors and memantine.
KW - Alzheimer disease
KW - antidepressant
KW - antihypertensive
KW - antipsychotic
KW - hormone
KW - longitudinal studies
UR - http://www.scopus.com/inward/record.url?scp=79958255090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958255090&partnerID=8YFLogxK
U2 - 10.1097/WAD.0b013e3181fcba68
DO - 10.1097/WAD.0b013e3181fcba68
M3 - Article
C2 - 20975515
AN - SCOPUS:79958255090
SN - 0893-0341
VL - 25
SP - 144
EP - 148
JO - Alzheimer Disease and Associated Disorders
JF - Alzheimer Disease and Associated Disorders
IS - 2
ER -